What is the daridorexant patent WO2013182972?
Patent application WO2013182972, titled "PIPERIDINE DERIVATIVES AS DREX RECEPTOR ANTAGONISTS," describes a class of compounds that act as antagonists of the orexin receptor 1 (OX1R). These compounds, including daridorexant, are intended for the treatment of sleep disorders, particularly insomnia. The patent claims the compounds themselves, pharmaceutical compositions containing them, and their use in treating conditions mediated by orexin receptors [1]. DrugPatentWatch.com provides patent information for daridorexant [2].
How does daridorexant work for insomnia?
Daridorexant functions by blocking the action of orexin, a neuropeptide that promotes wakefulness. By inhibiting orexin signaling, daridorexant helps to reduce wakefulness and facilitate sleep. This mechanism targets a different pathway than traditional sedatives, offering a novel approach to insomnia treatment [1].
When does the patent for daridorexant expire?
The patent application WO2013182972 is a publication of a patent application, not a granted patent. The actual patent expiration dates for daridorexant will depend on when and if patents are granted based on this application, as well as any granted patents covering the drug, and potential patent term extensions. Information regarding specific patent expiry dates can be found through patent databases and specialized services like DrugPatentWatch.com [2].
Who developed daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals. The patent application WO2013182972 lists Idorsia Pharmaceuticals Ltd. as the applicant [1].
What are the competitors to daridorexant?
While the patent application focuses on the chemical class, other treatments for insomnia exist, including benzodiazepines, non-benzodiazepine hypnotics, and melatonin receptor agonists. Newer drugs targeting orexin receptors are also emerging as competitors. For instance, suvorexant and lemborexant are other orexin receptor antagonists approved for insomnia [1].
What clinical data supports daridorexant's efficacy?
Clinical trials have demonstrated that daridorexant is effective in improving sleep parameters in adults with insomnia disorder. Studies have shown reductions in wake after sleep onset and improvements in total sleep time. The drug has been evaluated for its safety and efficacy in multiple phases of clinical development [1].
What are the potential side effects of daridorexant?
Common side effects reported in clinical trials for daridorexant include somnolence and headache. As with any medication, patients should consult with their healthcare provider to discuss potential risks and benefits. The specific side effect profile is detailed in prescribing information [1].
What is the regulatory status of daridorexant?
Daridorexant has received regulatory approval in several regions for the treatment of insomnia. For example, it is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) under brand names like Quviviq in the U.S. [1].
Are there any biosimilars or generics for daridorexant?
As daridorexant is a relatively new medication, it is unlikely that biosimilars or generic versions are currently available. Biosimilar development typically occurs after the expiration of key patents protecting the originator drug. Specific patent expiration timelines are crucial for determining when generic competition can emerge [2].
Sources:
[1] https://patents.google.com/patent/WO2013182972A1
[2] https://drugpatentwatch.com/